Figure 5.

Meta-analysis comparing effects of short- and long-acting GLP-1 receptor agonists added to basal insulin in HbA_1c (A), HbA_1c target (≤7.0%) achievement (B), fasting plasma glucose (C), and body weight (D). For each variable, the results were significantly better for long-acting compounds (liraglutide, once-weekly exenatide, dulaglutide, and semaglutide based on 6 studies) compared to short-acting compounds (exenatide b.i.d. and lixisenatide based on 8 studies). Both studies with free and fixed-dose combinations were analyzed. Modified from [50].